英国儿童肺动脉高压国家服务中心二十年诊疗经验与结局
该研究回顾了英国儿童肺动脉高压国家服务中心2001至2021年连续接诊的1353例患儿,其中1101例确诊肺动脉高压,中位年龄2.6岁。最常见的类型为肺动脉高压(48%),其次为肺部疾病所致肺动脉高压(32.3%)。年发病率为3.5/百万儿童,患病率为18.1/百万。82.4%的患儿接受了肺动脉高压治疗,13.1%需升级至三联治疗。970例新发患者的1年无移植生存率为86.7%,10年为68.6%;左心疾病所致肺动脉高压生存率最低。
要点
- 儿童肺动脉高压表型异质且重叠,16.9%的患儿具有一种以上诊断分组的特征。
- 婴儿期肺部疾病所致肺动脉高压发病率最高,为15.0/百万/年。
- 尽管广泛使用肺动脉高压治疗,儿童肺动脉高压的长期预后仍较差。
核心结论
- 儿童肺动脉高压临床表型异质且重叠,并随儿童期演变;尽管广泛使用肺动脉高压治疗,预后仍较差。
研究设计与样本
- 回顾性队列研究,纳入2001年至2021年英国国家儿童肺动脉高压服务中心连续接诊的患儿,对新发患者进行生存分析。
主要发现
- 1353例评估患儿中1101例(81.4%)确诊肺动脉高压,女性占51%,中位年龄2.6岁(IQR 0.8-8.2)。
- 肺动脉高压占48%,肺部疾病所致肺动脉高压占32.3%,16.9%的患儿具有一种以上诊断分组的特征。
- 儿童肺动脉高压年发病率为3.5/百万(95%CI 3.3-3.8),患病率为18.1/百万(95%CI 15.8-20.4)。
- 婴儿期肺部疾病所致肺动脉高压发病率最高,为15.0/百万/年(95%CI 12.7-17.2)。
- 970例新发患者1年无移植生存率为86.7%(95%CI 84.5-89%),10年为68.6%(95%CI 64.7-72.6%)。
关键数值与推荐
- 82.4%的患者接受了肺动脉高压治疗,13.1%在随访期间需升级至三联治疗。
- 左心疾病所致肺动脉高压生存率最低(HR 2.0;95%CI 1.36-2.94;P < 0.001)。
临床怎么用
- 儿童肺动脉高压需考虑多重病因重叠,评估时应全面排查相关疾病。
- 婴儿期肺部疾病相关肺动脉高压发病率高,应加强早期识别与随访。
- 左心疾病所致肺动脉高压预后最差,需密切监测并优化管理。
局限性
- 本研究为单中心国家服务中心的回顾性分析,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Pediatric pulmonary hypertension is an important cause of childhood morbidity and mortality, but there are limited data on the range of associated diseases, contributions of different pulmonary hypertension subtypes, therapeutic strategies, and clinical outcomes in children. Objectives: To report the 20-year experience of a large UK National Pediatric Pulmonary Hypertension Service focusing on epidemiology and clinical outcomes. Methods: Consecutive patients presenting between 2001 and 2021 were included, and survival analysis was performed for incident patients. Measurements and Main Results: Of 1,353 patients assessed, a pulmonary hypertension diagnosis was made in 1,101 (81.4%) patients (51% female, median age, 2.6 [interquartile range, 0.8-8.2] years). The most common form was pulmonary arterial hypertension in 48%, followed by 32.3% with pulmonary hypertension due to lung disease. Multiple contributory causes of pulmonary hypertension were common, with 16.9% displaying features of more than one diagnostic group. The annual incidence of childhood pulmonary hypertension was 3.5 (95% confidence interval [CI], 3.3-3.8) per 1 million children, and the prevalence was 18.1 (95% CI, 15.8-20.4) per 1 million. The incidence was highest for pulmonary hypertension due to lung disease in infancy (15.0 [95% CI, 12.7-17.2] per 1 million per year). Overall, 82.4% patients received pulmonary arterial hypertension therapy, and escalation to triple therapy during follow-up was required in 13.1%. In 970 (88.1%) incident patients, transplant-free survival was 86.7% (95% CI, 84.5-89%) at 1 and 68.6% (95% CI, 64.7-72.6%) at 10 years. Pulmonary hypertension due to left heart disease had the lowest survival (hazard ratio, 2.0; 95% CI, 1.36-2.94; P < 0.001). Conclusions: Clinical phenotypes of pediatric pulmonary hypertension are heterogeneous and overlapping, with clinical phenotypes that evolve throughout childhood. Despite widespread use of pulmonary arterial hypertension therapy, the prognosis remains poor.
引用
- Constantine A, Dimopoulos K, Haworth SG, et al. Twenty-Year Experience and Outcomes in a National Pediatric Pulmonary Hypertension Service. Am J Respir Crit Care Med. 2022. PMID: 35579610. doi:10.1164/rccm.202110-2428OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。